May 12, 2023 06:41 PM EDTUpdated May 16, 06:54 PM
R&D

Proxy ad­vis­er ISS sup­ports on­ly one of Ic­ah­n's can­di­dates for Il­lu­mi­na board

Jared Whitlock

Features Editor

A sec­ond proxy ad­vis­er firm is­sued a neg­a­tive opin­ion of Il­lu­mi­na’s gov­er­nance in the midst of its fight with in­vestor Carl Ic­ahn, an­oth­er blow to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times